Summary
The aim of the investigation was to see if the histological diagnosis of brain tumors showing an intermediate degree of malignancy can be improved by the measurement ofl-α-alanine inhibition of pyruvate kinase isoenzymes. The inhibition of pyruvate kinase activity was measured in 51 gliomas with different grades of malignancy. It was confirmed that benign tumors have a low level of inhibition (less than 50%) and that the more malignant the tumor, the higher the level of inhibition became, reaching more than 75%. However, when grade II and III astrocytomas and grade II and III oligodendrogliomas were analyzed, their level of inhibition was found to be variable. Grade II showed low and moderate levels of inhibition and grade III moderate and high levels. In turn, inhibition levels ranging from 50 to 75% were not only found in brain tumors with an intermediate grade of malignancy, but also in a number of benign and malignant tumors. When the survival times of patients with brain tumors were compared with both the histological diagnosis and pyruvate kinase inhibition, the prediction of the survival time on the basis of low and high levels of inhibition correlated well with the histological diagnosis. In contrast, when moderate levels of inhibition were measured, the prediction of the patients' survival remained uncertain and no improvement was found in the prediction for tumors showing an intermediate degree of malignancy on the basis of histology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bücher T, Pfleiderer G (1955) Pyruvate kinase from muscle. Methods Enzymol 1:435–440
Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, Westin EH, Wong-Staal F, Gallo RC, Aaronson SA (1982) Cellular genes analogous to tetroviral one genes are transcribed in human tumor cells. Nature 295:116–119
Farron F, Hsu HHT, Know WE (1972) Fetal type isoenzymes in hepatic and non-hepatic rat tumors. Cancer Res 32:302–306
Gerhardt W, Clause J, Christenen E, Rishede J (1967) Lactate dehydrogenase isoenzymes in the diagnosis of human benign and malignant brain tumors. J Natl Cancer Inst 38:343–357
Graham JM (1979) Surface of normal and malignant cells. Wiley, Toronto, pp 199–286
Hall A, Marshall CJ, Spur NK, Weiss RA (1983) Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome. 1. Nature 303:396–400
Ibsen KH (1977) Interrelationships and functions of the pyruvate kinase isoenzyme and their variant forms: a review. Cancer Res 37:341–353
Ibsen KH, Fischman WH (1979) Developmental gene expression in cancer. Biochim Biophys Acta 560:243–280
Kit S (1976) Thymidine kinase, DNA syntheses and cancer. Mol Cell Biochem 11:161–182
Kohl NE, Kanda N, Schreck RR, Bruns G, Laft SA, Gilbert F, Alt FW (1983) Transposition and amplification of oncogene related sequences in human neuroblastomas. Cell 35:359–367
Nicholson GL, Poste G (1976) The cancer cell: dynamic aspects and modifications in cell surface organisation. N Engl J Med 295:197–203
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 312:513–516
Schwartz M (1978) Enzymes and cancer. In: Ruddon RW (ed) Biological markers of neoplasia: a basic and applied aspect. Elsevier, Amsterdam, p 103
Spence AM (1980) Lactic dehydrogenase in ethylnitrosuria-induced rat gliomas. Oncology 36:260–264
Swab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J (1983) Amplified DNA with limited homology tomyc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 305:245–248
Tolle SW, Dyson RD, Newburgh RW, Cardenas JM (1976) Pyruvate kinase isoenzymes in neurons, glia, neuroblastoma and glioblastoma. J Neurochem 27:1355–1360
Van Veelen CWM, Staal GEJ, Verbiest H, Vlug AMC (1977) Alanine inhibition of pyruvate kinase in gliomas and meningiomas. Lancet II:384–385
Van Veelen CWM, Verbiest H, Vlug AMC, Rijksen G, Staal GEJ (1978) Isoenzymes of pyruvate kinase from human brain, meningiomas and malignant gliomas. Cancer Res 38:4681–4687
Van Veelen CWM, Verbiest H, Zülch K, Van Ketel BA, Van der Vlist MJM, Vlug AMC, Rijksen G, Staal GEJ (1979)l-α-Alanine inhibition of pyruvate kinase from tumors of the human central nervous system. Cancer Res 39:4263–4269
Van Veelen CWM, Rijksen G, Vlug AMC, Staal GEJ (1981) Correlation between alanine inhibition of pyruvate kinase and composition of K-M hybrids. Clin Chim Acta 110: 113–120
Van Veelen CWM, Verbiest H, Zülch KJ, Van Ketel BA, Van der Vlist MJM, Vlug AMC, Rijksen G, Staal GEJ (1982) Pyruvate kinase in human brain tumors. Its significance in the treatment of gliomas. Acta Neurochir (Wien) 61:145–159
Weber G (1977a) Enzymology of cancer cells. I. N Engl J Med 296:486–493
Weber G (1977b) Enzymology of cancer cells II. N Engl J Med 296:541–551
Zülch KJ (1979) Histological typing of tumours of the central nervous system. International histological classification of tumours, vol. 21. World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mostert, H.W.J., de Both, N.J., Rhijnsburger, E.H. et al. Pyruvate kinase inhibition in the diagnosis of gliomas with an intermediate degree of malignancy. Acta Neuropathol 70, 296–301 (1986). https://doi.org/10.1007/BF00686087
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686087